Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the signing of a Promotional Services Framework Agreement with Kelun Jiaxun, a subsidiary of its controlling shareholder Kelun Pharmaceutical. This agreement, effective from February 12, 2025, will see Kelun Jiaxun promote the company’s Cetuximab N01 Injection, an EGFR monoclonal antibody. The arrangement is classified as a continuing connected transaction under Hong Kong’s Listing Rules, which means it requires reporting and announcement but not independent shareholder approval due to its scope. The agreement underscores the company’s strategic efforts to enhance the market presence of its biopharmaceutical products, potentially benefiting stakeholders by leveraging the promotional capabilities of Kelun Jiaxun.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company specializes in developing monoclonal antibodies and other biopharmaceutical products, with a market focus on advanced therapeutic solutions.
YTD Price Performance: 8.82%
Average Trading Volume: 289,282
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$40.4B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.